Reduces methotrexate toxicity.

Enhances cytotoxic and neoplastic effects of fluorouracil

Increases risk of seizures in epileptic patients  treated with primidone, phenytoin, phenobarb
and succinimides

Reducing toxicity of Folic Acid antagonists- Methotrexate

Allergic sensitisation , rash, pruritus, eythema, urticaria, nausea, vomiting, pyrexia

Hypersensitivity- pernicious anemia and other megaloblastic anemias secondary to
vit B12 deficiency, intrathecal and intraventricular admin.

Special Precautions-
Undiagonised megaloblastic anemia, folate dependent , tumors, pregnancy

Monitor Ca levels in patients receiving combined 5-Fluorouracil/ folic acid treatment

To be given parentrally in the presence of GI toxicity, nausea, or vomiting

Monitor  CBC  , electrolyte and liver function tests before and regularly during treatment
 

Indication-
Reducing toxicity of Folic Acid antagonists- Methotrexate

Dosage-

Do not mix with 5-FU in same inj or infusion .
Dose equal to or more than methotrexate given usually 75mg by i.v. infusion followed by
12mg by i.m. 6 hourly  in severe toxicity

Less severe cases- 6-12mg i.m.  6 hourly  for 4 doses

Children- not recommended

Use contraindicated during pregnancy and lactation.
Observe caution if required to be administered